UNASSIGNED: OBJECT @entity16 ( @entity16 ) and @entity2553 ( @entity2553 ) are responsible fora poor outcome in @entity1 with @entity510 ( @entity510 ), most likely because of a decreased availability of @entity842 (NO) in the cerebral microcirculation. In this study, the authors examined the effects of treatment with the NO donor @entity17728 with regard to decreasing the incidence of @entity2473 -related delayed @entity4798 and improving clinical outcome in @entity1 with @entity510 . METHODS Seventy-four @entity1 with spontaneous @entity439 @entity510 were included in this post hoc analysis. Twenty-nine @entity1 with @entity510 and proven @entity2553 received @entity17728 in addition to oral or intravenous @entity3931 . Control groups consisted of 25 @entity510 @entity1 with proven @entity2553 and 20 @entity510 @entity1 without. These @entity1 received @entity3931 therapy alone. Cranial computed tomography (CCT) before and after treatment was analyzed for @entity2553 -related @entity1188 . A modified National Institutes of Health @entity64 Scale (mNIHSS) and the modified Rankin Scale (mRS) were used to assess outcomes at a 3-month clinical follow-up. RESULTS Four of the 29 (13.8%) @entity1 receiving @entity17728 plus @entity3931 and 22 of the 45 (48%) @entity1 receiving @entity3931 therapy alone developed @entity2553 -associated @entity4798 (p < 0.01). Follow-up revealed a median mNIHSS score of 3.0 and a median mRS score of 2.5 in the @entity17728 group compared with scores of 11.5 and 5.0, respectively, in the @entity3931 group with @entity2553 (p < 0.001). One @entity1 in the @entity17728 treatment group died, and 12 @entity1 in the standard care group died (p < 0.01). CONCLUSIONS In this post hoc analysis, @entity1 with @entity2553 who were treated with intravenous @entity17728 had a significant improvement in clinical outcome and less @entity385 . @entity17728 offers a promising therapeutic option in @entity1 with severe @entity510 and @entity2553 and should be assessed in a prospective study.

@entity17728 for the prevention of XXXX -related delayed ischemic neurological deficits and delayed @entity4798 and the improvement of clinical outcome after @entity510 : a single-center clinical observational study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity4798 :: ('MESH:D020520', 'Disease') :: ['brain infarcts', 'brain infarctions'] @entity64 :: ('MESH:D020521', 'Disease') :: ['Stroke'] @entity510 :: ('MESH:D013345', 'Disease') :: ['aneurysmal subarachnoid hemorrhage', 'SAH'] @entity16 :: ('MESH:D009422', 'Disease') :: ['Delayed ischemic neurological deficits', 'DINDs'] @entity3931 :: ('MESH:D009553', 'Chemical') :: ['nimodipine'] @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysmal'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity2473 :: ('MESH:D013035', 'Disease') :: ['spasm'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarcts'] @entity2553 :: ('MESH:D020301', 'Disease') :: ['cerebral vasospasm', 'CVS', 'vasospasm'] @entity385 :: ('MESH:D002544', 'Disease') :: ['cerebral infarction'] @entity17728 :: ('MESH:D008981', 'Chemical') :: ['molsidomine', 'Molsidomine']
@entity2553 :: (MESH:D020301,Disease) :: ['vasospasm']
